Williams Jones & Associates LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.9% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,850 shares of the company’s stock after acquiring an additional 1,070 shares during the period. Williams Jones & Associates LLC’s holdings in Eli Lilly and were worth $975,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Logan Capital Management Inc. grew its holdings in shares of Eli Lilly and by 0.8% in the second quarter. Logan Capital Management Inc. now owns 28,279 shares of the company’s stock worth $2,327,000 after purchasing an additional 229 shares during the last quarter. AHL Partners LLP grew its holdings in shares of Eli Lilly and by 127.4% in the second quarter. AHL Partners LLP now owns 67,347 shares of the company’s stock worth $5,543,000 after purchasing an additional 37,725 shares during the last quarter. Salem Investment Counselors Inc. grew its holdings in shares of Eli Lilly and by 25.9% in the second quarter. Salem Investment Counselors Inc. now owns 45,060 shares of the company’s stock worth $3,708,000 after purchasing an additional 9,260 shares during the last quarter. Sun Life Financial INC grew its holdings in shares of Eli Lilly and by 15,975.0% in the second quarter. Sun Life Financial INC now owns 7,073 shares of the company’s stock worth $582,000 after purchasing an additional 7,029 shares during the last quarter. Finally, Institute for Wealth Management LLC. bought a new position in shares of Eli Lilly and in the second quarter worth about $1,063,000. Institutional investors and hedge funds own 76.61% of the company’s stock.

A number of research analysts have recently commented on LLY shares. UBS AG cut shares of Eli Lilly and to a “hold” rating and set a $85.00 price target on the stock. in a report on Wednesday, July 26th. BMO Capital Markets restated a “sell” rating and issued a $71.00 price target on shares of Eli Lilly and in a report on Thursday, September 28th. Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the stock a “hold” rating in a report on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a report on Friday, October 13th. Finally, Berenberg Bank restated a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Hold” and an average target price of $89.76.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 190,000 shares of the stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the completion of the sale, the insider now directly owns 123,682,287 shares of the company’s stock, valued at $10,207,499,146.11. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares in the company, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 772,003 shares of company stock valued at $64,837,441. Insiders own 0.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Williams Jones & Associates LLC Has $975,000 Holdings in Eli Lilly and Company (LLY)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/21/williams-jones-associates-llc-has-975000-holdings-in-eli-lilly-and-company-lly.html.

Shares of Eli Lilly and Company (LLY) opened at $83.18 on Tuesday. The company has a market cap of $91,590.00, a PE ratio of 20.27, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34. Eli Lilly and Company has a 1 year low of $64.18 and a 1 year high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.88 earnings per share. equities research analysts predict that Eli Lilly and Company will post 4.21 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is 99.05%.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.